Exogenous and Endogenous Cannabinoids Suppress Inhibitory Neurotransmission in the Human Neocortex

Overview

Journal Neuropsychopharmacology

Date 2011 Nov 4

PMID 22048459

Citations 14

Authors

Flora E Kovacs

Tim Knop

Michal J Urbanski

Ilka Freiman

Thomas M Freiman

Thomas J Feuerstein

Josef Zentner

Bela Szabo

Affiliations

Soon will be listed here.

Abstract

Activation of CB(1) receptors on axon terminals by exogenous cannabinoids (eg, Δ(9)-tetrahydrocannabinol) and by endogenous cannabinoids (endocannabinoids) released by postsynaptic neurons leads to presynaptic inhibition of neurotransmission. The aim of this study was to characterize the effect of cannabinoids on GABAergic synaptic transmission in the human neocortex. Brain slices were prepared from neocortical tissues surgically removed to eliminate epileptogenic foci. Spontaneous GABAergic inhibitory postsynaptic currents (sIPSCs) were recorded in putative pyramidal neurons using patch-clamp techniques. To enhance the activity of cannabinoid-sensitive presynaptic axons, muscarinic receptors were continuously stimulated by carbachol. The synthetic cannabinoid receptor agonist WIN55212-2 decreased the cumulative amplitude of sIPSCs. The CB(1) antagonist rimonabant prevented this effect, verifying the involvement of CB(1) receptors. WIN55212-2 decreased the frequency of miniature IPSCs (mIPSCs) recorded in the presence of tetrodotoxin, but did not change their amplitude, indicating that the neurotransmission was inhibited presynaptically. Depolarization of postsynaptic pyramidal neurons induced a suppression of sIPSCs. As rimonabant prevented this suppression, it is very likely that it was due to endocannabinods acting on CB(1) receptors. This is the first demonstration that an exogenous cannabinoid inhibits synaptic transmission in the human neocortex and that endocannabinoids released by postsynaptic neurons suppress synaptic transmission in the human brain. Interferences of cannabinoid agonists and antagonists with synaptic transmission in the cortex may explain the cognitive and memory deficits elicited by these drugs.

Citing Articles

Synaptic Targets and Cellular Sources of CB1 Cannabinoid Receptor and Vesicular Glutamate Transporter-3 Expressing Nerve Terminals in Relation to GABAergic Neurons in the Human Cerebral Cortex.

Somogyi P, Horie S, Lukacs I, Hunter E, Sarkany B, Viney T Eur J Neurosci. 2025; 61(1):e16652.

PMID: 39810425 PMC: 11733414. DOI: 10.1111/ejn.16652.

Technical report: surgical preparation of human brain tissue for clinical and basic research.

Straehle J, Ravi V, Heiland D, Galanis C, Lenz M, Zhang J Acta Neurochir (Wien). 2023; 165(6):1461-1471.

PMID: 37147485 PMC: 10227129. DOI: 10.1007/s00701-023-05611-9.

Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.

Scheyer A, Yasmin F, Naskar S, Patel S Neuropsychopharmacology. 2022; 48(1):37-53.

PMID: 36100658 PMC: 9700791. DOI: 10.1038/s41386-022-01438-7.

Cell type specific cannabinoid CB1 receptor distribution across the human and non-human primate cortex.

Chou S, Ranganath T, Fish K, Lewis D, Sweet R Sci Rep. 2022; 12(1):9605.

PMID: 35688916 PMC: 9187707. DOI: 10.1038/s41598-022-13724-x.

The altered state of consciousness induced by Δ9-THC.

Murray C, Srinivasa-Desikan B Conscious Cogn. 2022; 102:103357.

PMID: 35640529 PMC: 11849378. DOI: 10.1016/j.concog.2022.103357.

References

Kreitzer A, Carter A, Regehr W . Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron. 2002; 34(5):787-96. DOI: 10.1016/s0896-6273(02)00695-5. View

Stuart G, Dodt H, Sakmann B . Patch-clamp recordings from the soma and dendrites of neurons in brain slices using infrared video microscopy. Pflugers Arch. 1993; 423(5-6):511-8. DOI: 10.1007/BF00374949. View

Brown S, Safo P, Regehr W . Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J Neurosci. 2004; 24(24):5623-31. PMC: 6729326. DOI: 10.1523/JNEUROSCI.0918-04.2004. View

Fernandez-Ruiz J, Romero J, Velasco G, Tolon R, Ramos J, Guzman M . Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol Sci. 2006; 28(1):39-45. DOI: 10.1016/j.tips.2006.11.001. View

Van Sickle M, Duncan M, Kingsley P, Mouihate A, Urbani P, Mackie K . Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005; 310(5746):329-32. DOI: 10.1126/science.1115740. View

Hill E, Gallopin T, Ferezou I, Cauli B, Rossier J, Schweitzer P . Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol. 2007; 97(4):2580-9. DOI: 10.1152/jn.00603.2006. View

Marcaggi P, Attwell D . Endocannabinoid signaling depends on the spatial pattern of synapse activation. Nat Neurosci. 2005; 8(6):776-81. PMC: 2629534. DOI: 10.1038/nn1458. View

Patel S, Wohlfeil E, Rademacher D, Carrier E, Perry L, Kundu A . The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003; 139(5):1005-13. PMC: 1573928. DOI: 10.1038/sj.bjp.0705334. View

Kim J, Isokawa M, Ledent C, Alger B . Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci. 2002; 22(23):10182-91. PMC: 6758770. View

10.

Trettel J, Fortin D, Levine E . Endocannabinoid signalling selectively targets perisomatic inhibitory inputs to pyramidal neurones in juvenile mouse neocortex. J Physiol. 2004; 556(Pt 1):95-107. PMC: 1664891. DOI: 10.1113/jphysiol.2003.058198. View

11.

Kovacs F, Illes P, Szabo B . Purine receptor-mediated endocannabinoid production and retrograde synaptic signalling in the cerebellar cortex. Br J Pharmacol. 2010; 162(4):974-88. PMC: 3042206. DOI: 10.1111/j.1476-5381.2010.01106.x. View

12.

Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J . Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage. 2007; 39(4):1533-41. DOI: 10.1016/j.neuroimage.2007.10.053. View

13.

Kawaguchi Y . Selective cholinergic modulation of cortical GABAergic cell subtypes. J Neurophysiol. 1997; 78(3):1743-7. DOI: 10.1152/jn.1997.78.3.1743. View

14.

Brown S, Brenowitz S, Regehr W . Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat Neurosci. 2003; 6(10):1048-57. DOI: 10.1038/nn1126. View

15.

Kim J, Alger B . Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci. 2004; 7(7):697-8. DOI: 10.1038/nn1262. View

16.

Trettel J, Levine E . Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex. J Neurophysiol. 2002; 88(1):534-9. DOI: 10.1152/jn.2002.88.1.534. View

17.

Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K . Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience. 1998; 85(2):395-403. DOI: 10.1016/s0306-4522(97)00597-6. View

18.

Ludanyi A, Eross L, Czirjak S, Vajda J, Halasz P, Watanabe M . Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci. 2008; 28(12):2976-90. PMC: 6670708. DOI: 10.1523/JNEUROSCI.4465-07.2008. View

19.

Buczynski M, Parsons L . Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol. 2010; 160(3):423-42. PMC: 2931546. DOI: 10.1111/j.1476-5381.2010.00787.x. View

20.

Steffens M, Szabo B, Klar M, Rominger A, Zentner J, Feuerstein T . Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience. 2003; 120(2):455-65. DOI: 10.1016/s0306-4522(03)00318-x. View